The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.
Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.
California judge sentences two killers of a 13-year-old to anger management therapy americanthinker.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from americanthinker.com Daily Mail and Mail on Sunday newspapers.